Literature DB >> 30714986

Autoimmune seizures and epilepsy.

Christian Geis1, Jesus Planagumà2, Mar Carreño3, Francesc Graus2,3, Josep Dalmau2,3,4,5.   

Abstract

The rapid expansion in the number of encephalitis disorders associated with autoantibodies against neuronal proteins has led to an incremental increase in use of the term "autoimmune epilepsy," yet has occurred with limited attention to the physiopathology of each disease and genuine propensity to develop epilepsy. Indeed, most autoimmune encephalitides present with seizures, but the probability of evolving to epilepsy is relatively small. The risk of epilepsy is higher for disorders in which the antigens are intracellular (often T cell-mediated) compared with disorders in which the antigens are on the cell surface (antibody-mediated). Most autoantibodies against neuronal surface antigens show robust effects on the target proteins, resulting in hyperexcitability and impairment of synaptic function and plasticity. Here, we trace the evolution of the concept of autoimmune epilepsy and examine common inflammatory pathways that might lead to epilepsy. Then, we focus on several antibody-mediated encephalitis disorders that associate with seizures and review the synaptic alterations caused by patients' antibodies, with emphasis on those that have been modeled in animals (e.g., antibodies against NMDA, AMPA receptors, LGI1 protein) or in cultured neurons (e.g., antibodies against the GABAb receptor).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30714986      PMCID: PMC6391086          DOI: 10.1172/JCI125178

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  198 in total

1.  Brain immunohistopathological study in a patient with anti-NMDAR encephalitis.

Authors:  J-P Camdessanché; N Streichenberger; G Cavillon; V Rogemond; G Jousserand; J Honnorat; P Convers; J-C Antoine
Journal:  Eur J Neurol       Date:  2010-08-16       Impact factor: 6.089

2.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

3.  Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death.

Authors:  D Forrest; M Yuzaki; H D Soares; L Ng; D C Luk; M Sheng; C L Stewart; J I Morgan; J A Connor; T Curran
Journal:  Neuron       Date:  1994-08       Impact factor: 17.173

Review 4.  High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.

Authors:  Teresa Ravizza; Gaetano Terrone; Alessia Salamone; Federica Frigerio; Silvia Balosso; Daniel J Antoine; Annamaria Vezzani
Journal:  Brain Behav Immun       Date:  2017-10-13       Impact factor: 7.217

5.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

6.  Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies.

Authors:  Adaucto W Nóbrega-Jr; Christian P Gregory; Rachel Schlindwein-Zanini; Fabricio de Souza Neves; Peter Wolf; Roger Walz; Mario Steindel; Katia Lin
Journal:  Epilepsia       Date:  2018-08-26       Impact factor: 5.864

7.  Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus.

Authors:  Jainn-Jim Lin; Kuang-Lin Lin; Shao-Hsuan Hsia; Huei-Shyong Wang; I-Jun Chou; Yun-Tong Lin
Journal:  Pediatr Neurol       Date:  2012-10       Impact factor: 3.372

8.  Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy.

Authors:  M Toledano; J W Britton; A McKeon; C Shin; V A Lennon; A M L Quek; E So; G A Worrell; G D Cascino; C J Klein; T D Lagerlund; E C Wirrell; K C Nickels; S J Pittock
Journal:  Neurology       Date:  2014-04-04       Impact factor: 9.910

9.  Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies.

Authors:  Xiaoyu Peng; Ethan G Hughes; Emilia H Moscato; Thomas D Parsons; Josep Dalmau; Rita J Balice-Gordon
Journal:  Ann Neurol       Date:  2015-01-29       Impact factor: 10.422

10.  Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype.

Authors:  Sarosh R Irani; Charlotte J Stagg; Jonathan M Schott; Clive R Rosenthal; Susanne A Schneider; Philippa Pettingill; Rosemary Pettingill; Patrick Waters; Adam Thomas; Natalie L Voets; Manuel J Cardoso; David M Cash; Emily N Manning; Bethan Lang; Shelagh J M Smith; Angela Vincent; Michael R Johnson
Journal:  Brain       Date:  2013-09-06       Impact factor: 13.501

View more
  27 in total

Review 1.  Anti-NMDA receptor encephalitis: a review of mechanistic studies.

Authors:  Yue-Qiao Huang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-02-15

2.  When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.

Authors:  Bondish Kambadja; Houot Marion; Louis Cousyn; Nicolas Mezouar; Vincent Navarro; Bastien Herlin; Dupont Sophie
Journal:  J Neurol       Date:  2021-11-23       Impact factor: 4.849

Review 3.  Identification of clinically relevant biomarkers of epileptogenesis - a strategic roadmap.

Authors:  Michele Simonato; Denes V Agoston; Amy Brooks-Kayal; Chris Dulla; Brandy Fureman; David C Henshall; Asla Pitkänen; William H Theodore; Roy E Twyman; Firas H Kobeissy; Kevin K Wang; Vicky Whittemore; Karen S Wilcox
Journal:  Nat Rev Neurol       Date:  2021-02-16       Impact factor: 42.937

Review 4.  Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management.

Authors:  Elia Sechi; Eoin P Flanagan
Journal:  Front Neurol       Date:  2021-07-07       Impact factor: 4.003

5.  Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis.

Authors:  Yan Wang; Yi Yu; Yaping Hu; Ying Li; Fan Song; Ying Wang
Journal:  Front Neurol       Date:  2020-05-05       Impact factor: 4.003

Review 6.  Neuroinflammation: A Signature or a Cause of Epilepsy?

Authors:  Enrico Pracucci; Vinoshene Pillai; Didi Lamers; Riccardo Parra; Silvia Landi
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

7.  Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data.

Authors:  Anna Rada; Robert Birnbacher; Claudio Gobbi; Martin Kurthen; Albert Ludolph; Markus Naumann; Ulrike Neirich; Tim J von Oertzen; Gerhard Ransmayr; Matthias Riepe; Mareike Schimmel; Oliver Schwartz; Rainer Surges; Christian G Bien
Journal:  J Neurol       Date:  2020-10-06       Impact factor: 4.849

8.  Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.

Authors:  Romana Höftberger; Theodor W May; Christian G Bien; Corinna I Bien; Müjgan Dogan Onugoren; Desiree De Simoni; Verena Eigler; Carl-Albrecht Haensch; Martin Holtkamp; Fatme S Ismail; Martin Kurthen; Nico Melzer; Kristina Mayer; Felix von Podewils; Helmut Rauschka; Andrea O Rossetti; Wolf-Rüdiger Schäbitz; Olga Simova; Karsten Witt
Journal:  J Neurol       Date:  2020-04-03       Impact factor: 4.849

9.  Epilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic Conditions.

Authors:  Bernard S Chang; Vaishnav Krishnan; Chris G Dulla; Nathalie Jette; Eric D Marsh; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

Review 10.  Neurocritical care for Anti-NMDA receptor encephalitis.

Authors:  Kuang-Lin Lin; Jann-Jim Lin
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.